Studies have shown that PRDM16 and its related coregulatory factors PGC-1α and CTBP1/2 are potential targets for obesity-related therapy, controlling WAT-to-BAT conversion (Farmer, 2008). Here, PRDM16 is linked to obesity due to melanocortin 4 receptor deficiency.